Selegiline nanoparticle embedded transdermal film: An alternative approach for brain targeting in Parkinson's disease

Abstract

Present study was aimed to design and optimize ethylene vinyl acetate transdermal films containing selegiline-loaded poly (lactic-co-glycolic acid) nanoparticles for effective brain targeting along with its in-vitro and in-vivo evaluation. Transdermal film impregnated with SGN-NPs was developed by solvent casting technique utilizing 32 factorial design. Optimization was done by adding constrains on selected responses. FE-SEM study showed that the prepared nanoparticles were spherical with smooth surface, having particle size of 73.8 nm which were retained even after formulation of film. In-vivo study showed that repeated administration of low dose reserpine induces clinical signs of PD with significant increase in MAO-B level (215.11 ± 23.19 ng/g) and decrease in dopamine content (29.17 ± 6.39 ng/g) in rat brain tissues. Biodistribution study showed a 13-fold increase in extent of absorption with enhanced Tmax, t1/2 and MRT following SGN-NPs TDDS application with increased %DTE (136.87 ± 3.84 %) and %DTP (26.93 ± 4.29 %). Thus suggesting that SGN-NPs impregnated transdermal film can effectively target drug to the brain tissues and hence can be used an alternative approach for routine treatment of Parkinson disease.